Lakeside Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$626K Hold
522
– – 0.39% 42
2026
Q1
$480K Buy
522
+10
+2% +$10.1K 0.32% 44
2025
Q4
$550K Buy
512
+35
+7% +$33.5K 0.35% 41
2025
Q3
$364K Hold
477
– – 0.23% 48
2025
Q2
$372K Hold
477
– – 0.24% 46
2025
Q1
$394K Hold
477
– – 0.26% 46
2024
Q4
$368K Sell
477
-175
-27% -$145K 0.24% 46
2024
Q3
$578K Sell
652
-25
-4% -$22.5K 0.36% 38
2024
Q2
$613K Hold
677
– – 0.4% 37
2024
Q1
$527K Hold
677
– – 0.34% 39
2023
Q4
$395K Sell
677
-50
-7% -$29.2K 0.27% 44
2023
Q3
$390K Hold
727
– – 0.3% 40
2023
Q2
$341K Buy
+727
New +$305K 0.25% 47

Other funds holding LLY

Lakeside Advisors's LLY Position: Q2 2026 in Review

Lakeside Advisors held its Eli Lilly (LLY) position steady in Q2 2026 at 522 shares worth $626K. The position accounts for 0.39% of the portfolio, ranked #42.

Lakeside Advisors first reported a position in LLY in Q2 2023 and has held it in 13 quarters since. 4,641 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Lakeside Advisors held 522 shares of Eli Lilly worth $626K as of Q2 2026.
  • Lakeside Advisors left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 0.39% of Lakeside Advisors's portfolio in Q2 2026, its #42 holding.
  • Lakeside Advisors first reported a position in Eli Lilly in Q2 2023 and has held it in 13 quarters since.
  • 4,641 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Lakeside Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.